For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Arcus Biosciences Inc (NYSE: RCUS) closed at $13.09 down -2.82% from its previous closing price of $13.47. In other words, the price has decreased by -$2.82 from its previous closing price. On the day, 0.52 million shares were traded. RCUS stock price reached its highest trading level at $13.485 during the session, while it also had its lowest trading level at $13.07.
Ratios:
For a deeper understanding of Arcus Biosciences Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.23 and its Current Ratio is at 5.23. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on October 21, 2024, initiated with a Neutral rating and assigned the stock a target price of $20.
On October 08, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $29.
On November 18, 2022, BofA Securities started tracking the stock assigning a Neutral rating and target price of $33.BofA Securities initiated its Neutral rating on November 18, 2022, with a $33 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 31 ’24 when Goeltz II Robert C. sold 3,594 shares for $15.00 per share. The transaction valued at 53,910 led to the insider holds 60,138 shares of the business.
Goeltz II Robert C. bought 3,594 shares of RCUS for $53,910 on Dec 31 ’24. On Dec 02 ’24, another insider, Azoy Alexander, who serves as the Chief Accounting Officer of the company, sold 201 shares for $15.32 each. As a result, the insider received 3,079 and left with 19,070 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCUS now has a Market Capitalization of 1197886848 and an Enterprise Value of 187886960. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.55 while its Price-to-Book (P/B) ratio in mrq is 2.12. Its current Enterprise Value per Revenue stands at 0.714 whereas that against EBITDA is -0.652.
Stock Price History:
The Beta on a monthly basis for RCUS is 0.84, which has changed by -0.11030382 over the last 52 weeks, in comparison to a change of 0.25219524 over the same period for the S&P500. Over the past 52 weeks, RCUS has reached a high of $20.31, while it has fallen to a 52-week low of $12.88. The 50-Day Moving Average of the stock is -14.29%, while the 200-Day Moving Average is calculated to be -17.46%.
Shares Statistics:
For the past three months, RCUS has traded an average of 704.73K shares per day and 715320 over the past ten days. A total of 91.50M shares are outstanding, with a floating share count of 49.27M. Insiders hold about 46.16% of the company’s shares, while institutions hold 54.53% stake in the company. Shares short for RCUS as of 1736899200 were 8247597 with a Short Ratio of 11.70, compared to 1734048000 on 7386723. Therefore, it implies a Short% of Shares Outstanding of 8247597 and a Short% of Float of 18.59.
